Additional Panel Screening Services for Immuno-Oncology Drug Discovery
Introduction Strategies What We Can Offer Workflow Why Choose Us Customer Reviews FAQs Contact Us
Introduction
Immuno-oncology drug discovery necessitates a deep understanding of complex cellular interactions and resistance mechanisms. Panel screening services at Creative Biolabs provide critical platforms to evaluate therapeutic candidates against diverse cancer models, including those engineered for specific targets, drug resistance, or to study unique phenomena like the ADC bystander effect. By leveraging vast cell line collections and advanced assay technologies, these services expedite the identification of potent and selective compounds, unravel resistance pathways, and guide the development of innovative treatments by offering comprehensive data on drug efficacy and mechanism of action.
Our specialized panel screening services are designed to address critical bottlenecks in immuno-oncology drug discovery by providing comprehensive insights into compound efficacy, mechanism of action, and resistance profiling. We offer solutions for screening potential anticancer compounds, assessing the bystander effect of ADCs, evaluating kinase activity and inhibitor specificity, and identifying effective agents against drug-resistant cancer cells. Our services yield precise data on compound potency, selectivity, and interactions within complex biological systems, enabling informed decisions at every stage of your drug development pipeline. Discover How We Can Help - Request a Consultation.
Strategies
-
Customized Panel Selection: We offer the flexibility to select specific cell lines from our extensive portfolio based on individual study requirements. This allows for a highly targeted screening process against specific cancer types, genetic backgrounds, or resistance mechanisms.
-
Phenotypic and Mechanistic Assays: Beyond simple viability, we offer a range of assays, including colony formation, apoptosis, and cell cycle analysis, to provide deeper insights into compound activity. For ADCs, we employ flow cytometry and image-based assays to quantify bystander effects.
-
High-Throughput and Automation: Our state-of-the-art automated systems facilitate high-throughput screening, enabling the efficient testing of multiple compounds across entire panels with high reproducibility and scalability.
-
Tailored Resistance Model Generation: We specialize in generating drug-resistant cell lines specifically tailored to meet the unique needs of your research, providing bespoke solutions for tackling drug resistance.
What We Can Offer
Creative Biolabs offers a robust suite of services within our Additional Panel Screening framework, each designed to address specific needs in immuno-oncology drug discovery:
Our Tumor Cell Panel Screening Service features over 600 tumor cell lines, including 100+ modified or drug-resistant models across major cancer types. It's ideal for compound screening and cancer research, with panels tailored to targets like KRAS and HER2. We offer 2D/3D viability, colony formation, apoptosis, and cell cycle assays. All screenings are high-throughput, automated, and standardized, delivering reproducible results with detailed data such as QC metrics and dose-response curves.
NovaBiomart's ADC Bystander Effect Screening Service evaluates ADC function in heterogeneous tumors. Using antigen-positive/negative and reporter lines, we assess viability, apoptosis, and payload diffusion via flow cytometry and live-cell imaging. This enables in-depth analysis of bystander toxicity, off-target risk, and ADC optimization, including linker stability and payload strength.
Our BaF3 Kinase Receptor Panel Service uses IL-3-independent, kinase-driven BaF3 lines to evaluate kinase-targeted drugs. With 300+ kinase-overexpressing lines (e.g., EGFR, KRAS), we offer broad profiling for specificity, off-target effects, and resistance analysis. Proliferation assays help determine compound impact on kinase activity and identify promising inhibitors.
Creative Biolabs provides 30+ drug-resistant cancer cell lines (e.g., lung, breast) covering key resistance mechanisms like KRAS G12C and EGFR mutations. This panel helps evaluate therapeutic efficacy, resistance patterns, and off-target effects. We also offer custom resistance model generation and screen compounds for effects on proliferation, apoptosis, and resistance disruption.
Workflow
We work with you to define project goals and select the most suitable cell panels from our extensive library—ranging from tumor and antigen-positive/negative cells to BaF3 kinase and drug-resistant lines—ensuring focused and effective screening.
We tailor assay conditions (e.g., plate format, serum level) to your needs. Available assays include 2D/3D viability, colony formation, apoptosis, and cell cycle. For ADC bystander studies, we offer real-time flow cytometry and imaging assays.
Utilizing state-of-the-art automated systems, we conduct high-throughput screening to efficiently test multiple compounds across selected cell panels. This ensures reproducible, scalable, and efficient data collection while minimizing experimental variability.
Our assays are performed under meticulously standardized conditions, ensuring high reproducibility and reliability of results. We collect comprehensive data, including dose-response curves, cell viability data, and other critical markers relevant to your study.
After screening, we provide a detailed analysis of the results, including data on the candidate's potency, resistance profile, and potential off-target effects.
-
Required Starting Materials:
To initiate our panel screening services, clients typically provide their therapeutic compounds (e.g., small molecules, antibodies, ADCs) and any specific target information or research objectives. Concrete examples include purified drug candidates in a specified concentration range, target protein sequences or known mutations, and details regarding desired assay readouts (e.g., cell viability, apoptosis, specific biomarker expression).
Why Choose Us?
Creative Biolabs offers distinct advantages through our extensive expertise and cutting-edge platforms, ensuring superior results and accelerated drug development.
-
Access to Diverse Cell Lines: We provide access to over 600 diverse tumor cell lines, including drug-resistant and genetically engineered models covering major cancer types such as breast, lung, colon, and prostate. Our BaF3 kinase receptor cell panel alone features over 300 kinase variants, covering an extensive range of mutations and targets.
-
Flexible and Comprehensive Assays: Our flexible assay formats include 2D/3D viability assays, apoptosis, colony formation, and cell cycle analysis, supporting both short- and long-term studies. We also offer specialized flow cytometry and image-based assays for real-time, quantitative insights into ADC bystander effects.
-
High-Throughput, Automated Screening: Our state-of-the-art automated systems ensure consistent, scalable, and reproducible data generation, significantly accelerating your drug discovery timeline.
-
Customization and Precision: We offer customized panels tailored to specific targets (e.g., KRAS, HER2, DDR) and specialize in generating drug-resistant cell lines tailored to meet specific research needs, enabling precise evaluation of drug efficacy and mechanism of action.
Customer Reviews
-
"The comprehensive tumor cell panel screening provided by Creative Biolabs has significantly improved our ability to identify novel compounds with broad anti-cancer activity. The detailed dose-response curves were instrumental." [Time], J. L. S****on.
-
"Using BaF3 kinase receptor cell panels at Creative Biolabs in our research has significantly facilitated the precise determination of kinase inhibitor specificity, allowing us to confidently advance our most promising candidates." [Time], A. M. B***n.
-
"Expertise at Creative Biolabs in generating and screening against drug-resistant cell lines was a game-changer for our project. Their customized approach helped us explore mechanisms of resistance and design more effective combination therapies." [Time], D. R. T*****r.
FAQs
What types of cancer cell lines are available in your tumor cell panels?
We offer a vast collection of over 600 cancer cell lines representing a broad spectrum of cancer types, including breast, lung, colon, prostate, and more, encompassing over 100 genetically modified or drug-resistant lines.
Can you generate custom cell panels for my specific research needs?
Yes, Creative Biolabs offers customized cell panels allowing you to select from an extensive portfolio of cancer cell lines based on individual study requirements and specific targets. We also specialize in generating drug-resistant cell lines tailored to your specific needs.
What assays are included in your screening services?
Our screening services include a wide range of assays such as 2D and 3D cell viability assays (for IC50/GI50 values), colony formation, apoptosis, and cell cycle analysis. For ADC bystander effect, we offer flow cytometry and image-based assays.
How do you ensure the reproducibility and reliability of your results?
Our assays are conducted under meticulously standardized conditions, ensuring high reproducibility and reliability. We also utilize automated systems for high-throughput screening to minimize experimental variability.
How to Contact Us
At Creative Biolabs we are dedicated to accelerating your immuno-oncology research by providing unparalleled insights and robust data through our advanced panel screening services. Whether you need to screen compounds against diverse tumor types, understand drug resistance mechanisms, evaluate kinase inhibitors, or assess ADC bystander effects, our expert team and cutting-edge platforms are here to support your success.
Contact Our Team for More Information and to Discuss Your Project.
